Toronto, ON - March 20, 2025 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has completed a shipment of LaNeo™ MDMA to the University of Washington. The Company believes this is the first such shipment of MDMA capsules to cross the American/Canadian border.
“While we’re incredibly pleased to have delivered a supply of LaNeo MDMA to the University of Washington, it has become apparent that cross-border trade is a major pain point for clients,” said Shane Morris, COO, PharmAla Biotech. “As such, the PharmAla team is working hard to alleviate these issues, and we look forward to announcing a solution soon.”
Appointment of Ali Taghva
PharmAla is furthermore pleased to announce that Mr. Ali Taghva will take on new responsibilities, acting as Chief Commercial Officer to the Company, as well as Counsel to the Company.
For more information, please visit www.PharmAla.ca, where you can sign up to receive regular news updates.